Cite
HARVARD Citation
Malka, D. et al. (2019). FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. European journal of cancer. pp. 97-106. [Online].